Literature DB >> 26721715

Metabolic profile of Guge Fengtong tablet in rat urine and bile after oral administration, using high-performance liquid chromatography coupled with electrospray ionization quadrupole time-of-flight mass spectrometry.

Su-Ling Zeng1, Ping Li2, E-Hu Liu3.   

Abstract

In the present study, we developed and validated a rapid analytical method using high performance liquid chromatography coupled with quadrupole time of flight mass spectrometry (HPLC-Q-TOF/MS) to investigate the metabolic profile of Guge Fengtong tablet (GGFTT), a traditional Chinese medicine. The urine and bile samples were collected with 24 h after oral administration of GGFTT. A total of 34 compounds, including 11 parent compounds and 23 metabolites were unambiguously or tentatively identified. Our results indicated that glucuronidation, oxidation and methylation were the major metabolic pathways of the constituents in GGFTT. In addition, the results of this work also demonstrated the feasibility of HPLC-ESI-Q-TOF/MS for reliable characterization of the in vivo metabolites from herbal preparations.
Copyright © 2015 China Pharmaceutical University. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Bile; Guge Fengtong tablet; HPLC-Q-TOF/MS; Metabolite; Urine

Mesh:

Substances:

Year:  2015        PMID: 26721715     DOI: 10.1016/S1875-5364(15)30103-5

Source DB:  PubMed          Journal:  Chin J Nat Med        ISSN: 1875-5364


  2 in total

Review 1.  Nanotechnology-based approaches applied to nutraceuticals.

Authors:  Akanksha R Singh; Prasanna Kumar Desu; Ramya Krishna Nakkala; Vanitha Kondi; Sushma Devi; Mohammad Sarwar Alam; Hinna Hamid; Rajani B Athawale; Prashant Kesharwani
Journal:  Drug Deliv Transl Res       Date:  2021-03-18       Impact factor: 4.617

Review 2.  The Applications and Features of Liquid Chromatography-Mass Spectrometry in the Analysis of Traditional Chinese Medicine.

Authors:  Bingyao Pang; Ying Zhu; Longqing Lu; Fangbing Gu; Hailong Chen
Journal:  Evid Based Complement Alternat Med       Date:  2016-11-10       Impact factor: 2.629

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.